Origen de la red de primer grado Brian Connolly.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
Public Company | Biotechnology | 16 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Brian Connolly a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
AMGEN INC. | Pharmaceuticals: Major | Comptroller/Controller/Auditor | |
Bausch & Lomb, Inc.
Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Medical Specialties | Corporate Officer/Principal | |
SALIX PHARMACEUTICALS, LTD. | Pharmaceuticals: Major | President | |
ARENA PHARMACEUTICALS | Pharmaceuticals: Major | Director of Finance/CFO | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
SHIRE | Pharmaceuticals: Major | Director of Finance/CFO | |
PellePharm, Inc.
PellePharm, Inc. BiotechnologyHealth Technology PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. The firm also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Michael Henderson, Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA. | Biotechnology | Founder | |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Dartmouth College | College/University | Undergraduate Degree | |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree | |
Stanford University | College/University | Doctorate Degree | |
Baker Botts LLP
Baker Botts LLP Miscellaneous Commercial ServicesCommercial Services Baker Botts LLP provides legal services. Its services include antitrust and compensation law, corporate, enforcement and investigations, environmental law, intellectual property, litigation, projects, real estate and construction, regulatory, and tax. The firm renders its services to banking and finance industry, energy and natural resources, manufacturing, and technological industries. The company was founded by Peter Gray in 1840 and is headquartered in Houston, Texas. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
MIRATI THERAPEUTICS | Biotechnology | Director of Finance/CFO | |
Arizona State University | College/University | Undergraduate Degree Undergraduate Degree | |
Azusa Pacific University | College/University | Masters Business Admin | |
Fordham University
Fordham University Other Consumer ServicesConsumer Services Fordham University provides college and university. It offers undergraduate colleges and graduate & professional schools. The company was founded in 1841 and is headquartered in Bronx, NY. | College/University | Graduate Degree | |
Haverford College | College/University | Undergraduate Degree | |
Prometheus Laboratories, Inc.
Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
The Rockefeller University | College/University | Doctorate Degree | |
Klauber & Jackson Llc
Klauber & Jackson Llc Miscellaneous Commercial ServicesCommercial Services Klauber & Jackson Llc is a private company based in Hackensack, NJ. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Therasis, Inc.
Therasis, Inc. Pharmaceuticals: MajorHealth Technology Therasis, Inc. develops oncology drugs. It offers oncology therapeutics for use as single agents or in combination therapy. The firm's proprietary technology, the Therasis Filter, represents a paradigm shift in the ability to discover therapeutic targets, their chemical inhibitors, and associated biomarkers and this platform integrates world-class expertise in high throughput screening, systems biology, cancer genetics and clinical research. The company was founded by Owen A. O'Connor and Riccardo Dalla-Favera in 2007 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member | |
Ropes & Gray LLP
Ropes & Gray LLP Miscellaneous Commercial ServicesCommercial Services Ropes & Gray LLP provides legal and private equity services. Its practice areas include asset management, banking, business and commercial litigation, business restructuring, capital markets and corporate governance and compliance. The company was founded in 1865 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
AXCA HEALPAR | Biotechnology | General Counsel General Counsel | |
Cornell Law School | College/University | Graduate Degree | |
PMV PHARMACEUTICALS, INC. | Miscellaneous Commercial Services | Director/Board Member | |
SURFACE ONCOLOGY, INC. | Biotechnology | Director/Board Member | |
Shire International GmbH (Switzerland)
Shire International GmbH (Switzerland) Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire International GmbH is a pharmaceutical company based in Zug, Switzerland. The Swiss company develops, manufactures, and markets pharmaceuticals. | Pharmaceuticals: Major | Investor Relations Contact | |
VIRIDIAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
PROMETHEUS BIOSCIENCES, INC. | Biotechnology | Chief Executive Officer | |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The private company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Pharmaceuticals: Major | Chief Executive Officer | |
Origin Biosciences, Inc.
Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The private company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Pharmaceuticals: Major | Chief Executive Officer | |
CoA Therapeutics, Inc.
CoA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., CoA Therapeutics, Inc. is a biotechnology company based in San Francisco, CA. The private company is targeting coenzyme-A (CoA) for patients with PKAN, organic acidurias, and other diseases of CoA sequestration. CoA plays a crucial role in energy metabolism and is implicated in a large number of disorders, from ultra-rare diseases like pantothenate kinase-associated neurodegeneration (PKAN) and organic acidurias (OAs), to common diseases such as type 2 diabetes. CoA Therapeutics is developing a novel small-molecule approach to modulate CoA levels by leveraging recent research about the CoA synthetic pathway. The company's approach and lead compounds are based on breakthrough scientific developments led by Suzanne Jackowski, Charles Rock, Richard Lee, and Stephen White at St. Jude Children's Research Hospital. | Pharmaceuticals: Major | Director/Board Member | |
Fortify Therapeutics, Inc.
Fortify Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Fortify Therapeutics, Inc. is a private company dedicated to developing a safe and effective treatment for patients with Leber's hereditary optic neuropathy (LHON), a rare mitochondrial genetic disorder that leads to loss of central vision predominantly in young adults. The company is based in Palo Alto, CA. LHON is driven by mutations in subunits of the NADH dehydrogenase complex, reducing the ability of the retinal cells to produce energy, resulting in their degeneration. Fortify Therapeutics is currently developing a localized therapy to bypass the dysfunctional metabolic pathway in this disease and provide an alternate source of energy to the retinal cells of LHON patients. | Pharmaceuticals: Major | Director/Board Member | |
Viridian LLC
Viridian LLC BiotechnologyHealth Technology Viridian LLC operates as a biopharmaceutical incubator. It focuses in the discovery and development of new molecular entities. The company was founded by Peter Harwin and Tomas Kiselak in 2016 and is headquartered in Philadelphia, PA. | Biotechnology | Founder Founder | |
BRIDGEBIO PHARMA, INC. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
Quartz Therapeutics, Inc. | Director/Board Member | ||
Adrenas Therapeutics, Inc. | Director/Board Member | ||
TheRas, Inc.
TheRas, Inc. Medical/Nursing ServicesHealth Services TheRas, Inc. engages in biotechnological research, which develops program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company is headquartered in Palo Alto, CA. | Medical/Nursing Services | Director/Board Member | |
Dermecular Therapeutics, Inc. | Director/Board Member | ||
APOGEE THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member Chief Executive Officer Chairman | |
DIANTHUS THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Director of Finance/CFO | |
LONGBOARD PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member |
Estadísticas
Internacional
Estados Unidos | 44 |
Suiza | 3 |
Irlanda | 2 |
Arabia Saudita | 2 |
Sectorial
Health Technology | 29 |
Consumer Services | 10 |
Commercial Services | 7 |
Health Services | 2 |
Operativa
Director/Board Member | 58 |
Corporate Officer/Principal | 40 |
Independent Dir/Board Member | 24 |
Undergraduate Degree | 12 |
Chairman | 11 |
Las relaciones más conectadas
Insiders | |
---|---|
Alison Lawton | 24 |
Jeffrey Albers | 14 |
Michael Henderson | 14 |
Russell Cox | 13 |
Laurie Stelzer | 13 |
Peter Harwin | 11 |
Tomas Kiselak | 10 |
Mark Mckenna | 10 |
Cameron Turtle | 10 |
Paul Fehlner | 10 |
Heidy Abreu King-Jones | 8 |
Scott Burrows | 4 |
Scott W. Rowlinson | 2 |
Joshua Friedman | 1 |
Deanna Nguyen | 1 |
- Bolsa de valores
- Insiders
- Brian Connolly
- Conexiones Empresas